Reports revenue $9.1M vs. $7.8M last year. “2024 has been a successful year for International Stem Cell (ISCO) Corporation, marked by both strong financial performance and continued progress in our clinical trial. Our revenue growth, coupled with a significant reduction in operational losses, underscores the strength of our business model and the demand for our biomedical products. At the same time, we remain committed to advancing our pioneering ISC-hpNSC program, building upon the promising interim results observed in our Phase 1 clinical trial. Looking ahead, we are focused on leveraging these achievements to drive further growth, accelerate our research, and enhance value for our shareholders,” stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.